Titre :

A revised international prognostic score system for waldenstr�m''s macroglobulinemia

Auteur(s) :

Kastritis, Efstathios [Auteur]
Morel, Pierre [Auteur]
Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS]
Duhamel, Alain [Auteur]
Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS]
Gavriatopoulou, Maria [Auteur]
Kyrtsonis, Marie-Christine [Auteur]
Durot, Eric [Auteur]
Symeonidis, Argiris [Auteur]
Laribi, Kamel [Auteur]
Hatjiharissi, Evdoxia [Auteur]
Ysebaert, Loic [Auteur]
Vassou, Amalia [Auteur]
Giannakoulas, Nikolaos [Auteur]
Merlini, Giampaolo [Auteur]
Repousis, Panagiotis [Auteur]
Varettoni, Marzia [Auteur]
Michalis, Euridyki [Auteur]
Hivert, Benedicte [Auteur]
Michail, Michalis [Auteur]
Katodritou, Eirini [Auteur]
Terpos, Evangelos [Auteur]
Leblond, Véronique [Auteur]
Dimopoulos, Meletios A. [Auteur]

Titre de la revue :

Leukemia

Nom court de la revue :

Leukemia

Date de publication :

2019-05-22

ISSN :

1476-5551

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

A staging system was developed a decade ago for patients with Waldenström's macroglobulinemia (WM), however, since then WM treatments have changed. A revised staging system could better capture prognosis of WM patients in ...
Lire la suite >A staging system was developed a decade ago for patients with Waldenström's macroglobulinemia (WM), however, since then WM treatments have changed. A revised staging system could better capture prognosis of WM patients in the chemoimmunotherapy era. We developed a revised system based on data from 492 symptomatic patients with at least 3 years and a median of 7 years of follow up while an independent validation cohort included 229 symptomatic patients. We identified age (≤65 vs 66-75 vs ≥76 years), b2-microglobulin ≥ 4 mg/L, serum albumin <3.5 gr/dl, and LDH ≥ 250 IU/L (ULN < 225) to stratify patients in five different prognostic groups and identify a very-low risk as well as a very-high risk group with a 3-year WM-related death rate of 0, 10, 14, 38, and 48% (p < 0.001) and 10-year survival rate of 84, 59, 37, 19, and 9% (p < 0.001). We evaluated this staging system separately in patients >65 years and <65 years, according to the reason for initiation of treatment, among patients receiving frontline rituximab or in patients treated primarily without rituximab. With further validation before clinical use, this revised IPSSWM could improve WM patient risk stratification, is easily available and may be used in the everyday practice to provide prognostic information.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

CHU Lille
Université de Lille

Collections :

• METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694

Date de dépôt :

2019-12-09T16:48:07Z